Wrn Helicase

New Drug HRO761 Offers Targeted Hope for MSI Cancers, Including ICI-Resistant Cases

HRO761, a novel drug targeting the Werner syndrome helicase (WRN), shows promise for MSI cancers, including those resistant to immune checkpoint inhibitors. Currently in Phase 1 trials, it exploits synthetic lethality to selectively inhibit tumor growth.